Table 4 Outcomes of cardiotoxicity-related adverse event for Con-DOX and Lip-DOX in FAERS. (Con-DOX, conventional doxorubicin; Lip-DOX, liposomal doxorubicin).
Outcome | Con-COX | Lip-COX | ||
|---|---|---|---|---|
Cases, n | Proportion, % | Cases, n | Proportion,% | |
Non-Serious | 7 | 1.26% | 6 | 1.39% |
Serious: | 550 | 98.74% | 426 | 98.61% |
Life-Threatening | 56 | 10.05% | 55 | 12.73% |
Hospitalization—Initial or Prolonged | 209 | 37.52% | 128 | 29.63 |
Disability | 4 | 0.72% | 2 | 0.46% |
Death | 146 | 26.21 | 100 | 23.15% |
Congenital Anomaly | 0 | 0 | 0 | 0 |
Required Intervention to Prevent Permanent Impairment/Damage | 0 | 0 | 0 | 0 |
Other | 369 | 66.25% | 368 | 85.19% |
